|
|   |
Bristol Myers Squibb Co.
| Headquarters location: 345 Park Avenue New York, NY 10154 |  | Tel. 212-546-4000 Job offers, investor relations: www.bms.com Stock:  |
|
Bristol Myers Squibb belongs to |
| shareholder | country  % source |
|
Bristol Myers Squibb owns |
| subsidiary | country  % source |
|
|
name  items photo compare the prices |
Shop local, ethical and at the best price on Ethishop ! |
|
|
« ETHICAL » RATING OF BRISTOL_MYERS_SQUIBB
, group
and subsidiaries
[ ?] |
| Job: 14% of company's jobs cut since 1998 |
| Environment: 1 major pollution(s) |
| Delinquency: 7 act(s) of financial or trade delinquency |
| Tax haven, secret bank account, shell companies: operates in 14 offshore financial center(s) |
| Sales: more than 19 billion(s) dollars/euros in annual sales |
| Net profit: more than 27 billion(s) dollars/euros in cumulated net profit since 1998 |
| Top management: earns 1048 times the median income in the United States (32000 US$/year) |
| Influence: 10 act(s) of direct corruption or lobbying |
| Advertising & marketing: 2 dubious practice(s) |
|
|
Relevance: business & market share |
year | business source |
| 2006 | Bristol Myers Squibb is the world's thirteenth-largest pharmaceutical group. | Les Echos |
|
World locations & Manufacturing |
Bristol Myers Squibb is managed by |
year name | photo position; compensation source |
| 2002Dolan, Peter |  Chief Executive Officer; salary: 1.15 million US$; |
| 2000Dolan, Peter |  Chief Executive Officer; salary: 6.7 million US$; |
| 1998Heimbold, Charles |  Chief Executive Officer; salary: 3.19 million US$; stock-options: 30.37 million US$; |
|
year | dubious practice : image source |
| 2004 | Arguable partnership: Don pour les victimes du tsunami: 1000000 de dollars: value: Humanitaire; | AFP  |
| 2000 | Disinformation: PR campaign with Ketchum PR: public relations: K | PR Watch  |
|
|
year | employees <> | social impact : country source |
| 2007 | -4300 | Closure/Bankruptcy: Bristol Myers Squibb will cut its work force by 10 percent by 2010 and slash the number of its manufacturing plants by more than half, to generate an additional $1.5 billion in savings. Bristol Myers Squibb raised its 2008 earnings per share forecast, excluding special items, to $1.65 to $1.75 from a previous view of $1.60 to $1.70. That translates into an expectation of earnings growth next year of up to 19 percent.: | Reuters  |
| 2005 | -41 | Closure/Bankruptcy: Mise en vente de son centre de recherche et développement de Saint-Nazaire dans le cadre d'un regroupement de sa recherche. Si aucun repreneur ne se manifeste, cette unité sera fermée.: | Les Echos  |
| 2001 | 46000 | |  |
| 2001 | -1000 | | AP  |
| 2001 | -50 | |  |
| 1999 | 54700 | |  |
|
year | country : consequences source |
| 2005 | brand: Ability : Older patients with dementia who are given antipsychotic medicines are far more likely to die prematurely than those given placebos. Most died of heart-related problems like heart failure or infections like pneumonia (FDA) | New York T.  |
|
year | purpose : intermediary/lobby : institution source |
| 2001 | Access to foreign market (through MAI, WTO, GATS), prevent binding environmental regulations : USCIB (US Council For International Business) : : US Government translate | USCIB  |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington.  |
| 2000 | Investment protection and market access (to Mexico and Canada through NAFTA), to Latin America (through FTAA). : Business Roundtable : : US government, senate, congress translate | Center for.  |
| 2000 | Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translate | EFPIA  |
| 2000 | Prevent binding regulation, co- or self-regulation instead. : American Chamber of Commerce's EU Committee : : European Commission translate | Corporate .  |
| 1999 | Protection of Intellectual Property -TRIPS Agreement : Intellectual Property Committee : : WTO translate | Corporate .  |
| 1999 | Market access and investment protection (through WTO, GATS), avoid social and environmental rules : ICC (International Chamber of Commerce) : : WTO, GATS translate | Corporate .  |
| 1998 | Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 212 thousand US$ : US President, Congress, Senate translate | Center for.  |
| 1997 | Legislation favorable to company's interests : Direct donation : amount: 3780 thousand US$ : US President, Congress, Senate translate | Center for.  |
| 1997 | Legislation favorable to company's interests : Direct donation : amount: 631 thousand US$ : US President, Congress, Senate translate | Center for.  |
|
| year | donator | country | amount | source |
|
year | financial misdemeanor | sales | income | | buyback | source |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | |   | | Bloomberg  |
| 2005 |
Agreed to pay $300 million in a deal to defer federal prosecution of a conspiracy charge stemming from an accounting scandal. Frederick Schiff, Bristol-Myers former chief financial officer, and Richard Lane, former executive vice president and president of the worldwide medicines group, were indicted on charges of conspiracy and securities fraud. |
| | | |   | | AP  |
| 2005 |
Has paid about $155,000 to New Mexico as the state's share in the settlement of an antitrust lawsuit; aaccused of overcharging health care services for the cancer-fighting drug Taxol and Children's Motrin |
| | | |   | | AP  |
| 2004 |
Overstated profits from 1999 to 2002 by 700 millions US$ |
| | | |   | | Chicago Tr.  |
| 2004 |
Agreed to pay $150 million to settle U.S. Securities and Exchange Commission allegations that it inflated sales by misusing discounts and incentives to drug wholesalers. |
| | | |   | | Bloomberg  |
| 2003 |
Will pay about $670 million to settle allegations that it unlawfully delayed competition for its BuSpar anti-anxiety medication and Taxol cancer therapy. |
| | | |   | | Bloomberg  |
| 2002 |
| 18.12 | 2.07 | |   | billion US$ |  |
| 2002 |
SEC probe of sales practices: by offering incentives to wholesalers, BMS may have boosted revenue by as much as $1 billion. |
| | | |   | | CNN  |
| 2001 |
| 19.42 | 5.25 | |   | billion US$ |  |
| 2000 |
| 18.22 | 4.71 | |   | billion US$ |  |
| 1999 |
| 20.22 | 4.17 | |   | billion US$ |  |
| 1998 |
| 18.28 | 3.14 | |   | billion US$ |  |
| 1998 |
| | | | 2 | billion US$ |  |
|
|
|
|
Also announce a documentary, a book or an article or comment this company profile.
Goal: present the company activities, improve the ethical rating's accuracy, develop an network of observers.